Margarita V. Chebotareva

Margarita V. Chebotareva

Auto-generated profile, based on publicly available information

Margarita V. Chebotareva

Loginov Moscow Clinical Scientific Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NBNatalia Bodunova
Natalia Bodunova
LTLarisa Tsapkova
Larisa Tsapkova
ВПВера Полякова
Вера Полякова
IBIrina Baratova
Irina Baratova
KRKonstantin A. Rumyantsev
Konstantin A. Rumyantsev
Dmitry S BordinDmitry S Bordin
Dmitry S Bordin
The Maastricht VI/Florence consensus recommends, as one of the measures to enhance the efficacy of Helicobacter pylori infection eradication, a personalized treatment approach involving the selection of an antimicrobial agent based on the pre-determined resistance of H. pylori. To address the need to develop test systems for personalized drug selection, this study was designed to analyze the molecular resistance of H. pylori using a newly developed Sanger sequencing test platform. The characteristics of the test system were determined on 25 pure culture samples of H. pylori with known resistance. Sensitivity and specificity for detecting resistance to clarithromycin was 100% and those to levofloxacin were 93% and 92%, respectively. The test system has been tested in real clinical practice on 112 H. pylori-positive patients who had not previously received proton pump inhibitors (PPIs) or antibacterial drugs. Mutations indicating resistance to clarithromycin were found in 27 (24%) samples and those indicating resistance to levofloxacin were found in 26 (23%) samples. Double resistance was observed in 16 (14%) samples. The most common mutations leading to clarithromycin resistance were 2143G and 2142G and to levofloxacin resistance—261A and 271A in the gyrA gene, which account for 69% of all identified genetic determinants in levofloxacin-resistant bacteria. Thus, a personalized approach to the selection of H. pylori eradication therapy based on the detection of bacterial resistance before prescribing first-line therapy could help to avoid the prescription of ineffective H. pylori eradication therapies and, overall, contribute to the control of antibiotic resistance of H. pylori.

28 August 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MCM V Chebotareva
M V Chebotareva
KNK A Nikolskaya
K A Nikolskaya
DADmitrii Nikolaevich Andreev
Dmitrii Nikolaevich Andreev
ADA S Dorofeev
A S Dorofeev
SKSERGEY KHOMERIKI
SERGEY KHOMERIKI
Dmitry S BordinDmitry S Bordin
Dmitry S Bordin
Aim. To evaluate the possibility of using serum markers of atrophy (pepsinogens – PG I and II) to form high-risk groups for gastric cancer (Operative Link for Gastritis Assessment – OLGA stage III–IV) depending on the etiology of gastritis. Materials and methods. A total of 237 (56 men and 181 women) patients were examined. All patients underwent a 13C-urea breath test, a blood test for GastroPanel (PG I, PG II, gastrin-17, antibodies to Helicobacter pylori immunoglobulin G), a blood test for antibodies to gastric parietal cells. All patients underwent esophagogastroduodenoscopy with a biopsy of the gastric mucosa from 5 standard points according to the Sydney system and a histomorphological study according to the OLGA system, as well as a biopsy to detect H. pylori infection using the polymerase chain reaction. The patients were divided into 3 groups depending on the etiology of gastritis: Group 1 included 55 patients with chronic gastritis, autoimmune gastritis and associated with H. pylori gastritis (AIG+HP+); Group 2 – 47 patients with AIG and negative tests for H. pylori infection (AIG+HP-); Group 3 – 135 patients with chronic gastritis associated with H. pylori and negative markers of AIG (AIG-HP+). Results. The analysis showed that in patients with AIG (group 2), the most reliable serological markers of atrophy predicted severe atrophy (OLGA stage III–IV): when the ratio PG I/PG II was ≤ 3, it was detected in 70.21% of cases, and when PG I decreased to ≤ 30 μg/L, it was found in 68.08%. In group 1, stages III–IV according to OLGA were diagnosed in 20% of cases with PG I/PG II indicators ≤ 3; and in 18.18% with a decrease in PG I ≤ 30 μg/L. When analyzing the diagnostic accuracy of GastroPanel biomarkers in identifying severe atrophy (OLGA stages III–IV) in the total sample of patients (all 3 groups), it was possible to achieve cut-off indicators as close as possible to the reference values while maintaining a relatively high sensitivity and specificity – 75.81% and 81.50% for PG I ≤ 30 μg/L and 85.48% and 64.50% for PG I/PG II ≤ 3, respectively. The optimal cut-off in the study population for the PG I indicator was 22.5 μg/L (sensitivity – 72.58%, specificity – 88.00%), and for the PG I/PG II ratio ≤ 2 (sensitivity – 80.65%, specificity – 78.50%). Conclusion. Serum pepsinogens can be used in the Moscow population as a non-invasive marker of gastric mucosa atrophy for the formation of high-risk patient groups for gastric cancer requiring endoscopic examination.

6 October 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
OKO. V. Knyazev
O. V. Knyazev
AKAnna Kagramanova
Anna Kagramanova
ALA. А. Lischinskaya
A. А. Lischinskaya
ILI. А. Li
I. А. Li
ЕСЕ. А. Сабельникова
Е. А. Сабельникова
KNK. А. Nikolskaya
K. А. Nikolskaya
Introduction.The results of registrational clinical trials (CTs) and real clinical practice do not always correlate. The task of practitioners is to find optimal approaches to the therapy of Crohn’s disease, based on the analysis of clinical trials and real-world data.Aim.To make a retrospective assessment of the efficacy and tolerability of UST therapy in patients with moderate to severe CD in real clinical practice.Materials and methods.A total of 88 patients with CD were included in the study to evaluate the efficacy and safety of UST. Among the patients, men accounted for 48.9%, women – 51.1%, the average age was 36.4 ± 4.8 years, the disease duration was 7.8 ± 2.1 years. 67.1% of patients with moderate CD in the form of ileocolitis (82.9%) had a stenosing (26.1%) and penetrating (50.0%) form of the disease. 95.4% of patients received prior immunosuppressive therapy.Results.After inductive therapy with UST, clinical response and clinical remission within 8 weeks were recorded in 86 (97.7%) patients with CD. After 26 weeks, 58 (65.9%) patients achieved clinical remission, 28 (31.8%) patients with CD and all patients who responded to UST therapy maintained clinical response. Crohn’s Disease Activity Index (CDAI) decreased from 445.8 ± 50.4 to 134.6 ± 21.4 points. Clinically significant endoscopic improvement was reported in 25 (40.3%) of 62 patients, endoscopic response in 14 (22.6%) patients, endoscopic remission in 18 (29.0%). After 26 weeks, CDAI decreased from 7.8 ± 1.8 to 2.9 ± 1.2 points, after 52 weeks it decreased from 445.8 ± 50.4 to 141.6 ± 28.2. Steroid-free remission in CD patients accounted for 68.2%. 1-year survival of UST therapy was 97.7%, 2-year survival was 95.5%.Conclusions.The observation demonstrated the high efficacy of the drug in induction and maintenance therapy in the cohort of patients with severe to moderate CD resistant to disease-modifying and genetically engineered biological drugs.

27 December 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
Dmitry S BordinDmitry S Bordin
Dmitry S Bordin
KNKarine A. Nikolskaya
Karine A. Nikolskaya
MCMargarita V. Chebotareva
Margarita V. Chebotareva
IKIgor E. Khatkov
Igor E. Khatkov
Gastric cancer (GC) is one of the top five cancer morbidity and mortality rates in the Russian Federation and worldwide. Currently, there is a decrease in gastric cancer incidence, which is associated with a decrease in the prevalence of Helicobacter pylori infection. However, due to changes in the population structure and increased life expectancy, the absolute number of gastric cancer cases and mortality are expected to increase. GC is a consequence of long-term chronic gastritis. At least 90% of gastric cancers are caused by H. pylori. Reducing the incidence and mortality from GC is achievable with a reasonable combination of 2 strategies: primary prevention based on the detection and eradication of H. pylori, and secondary prevention, which is based on endoscopic screening of early GC and the formation of high-risk groups for cancer development and their subsequent endoscopic observation.

22 June 2024 in Effective Pharmacotherapy
Verified
Journal Article
Closed access
MCM.V. Chebotareva
M.V. Chebotareva
ACA.S. Loginov Moscow Clinical Scientific Center
A.S. Loginov Moscow Clinical Scientific Center
KNK.A. Nikolskaya
K.A. Nikolskaya
Dmitry S BordinDmitry S Bordin
Dmitry S Bordin
EPE.V. Parfenchikova
E.V. Parfenchikova
TUTver State Medical University
Tver State Medical University
Chronic atrophic gastritis (CAG) is the first stage of gastric carcinogenesis, which is why early diagnosis of the disease is important. The main etiological factors of CAG are Helicobacter pylori infection and autoimmune gastritis (AIG). The prevalence of H. pylori in the world is up to 43.1%, and in Russia – 36.4%. The prevalence of AIG is significantly lower and ranges from 0.5 to 4.6% and tends to increase. AIG is often diagnosed in the late stages of the disease due to an asymptomatic or low-symptomatic course, which should increase the alertness of endoscopists and gastroenterologists regarding this disease. Patients need long-term dynamic follow-up with EGDS and assessment of the stage of atrophy and the degree of inflammation according to OLGA (Operational Link for Gastritis Assessment). With AIG, the risk of developing neuroendocrine gastric tumors of the first type increases two to four times in comparison with healthy people. At the moment, there is no etiopathogenetic treatment for AIG. Symptomatic therapy with vitamin B12 and iron preparations is recommended if their deficiency is detected.

12 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NBNatalia Bodunova
Natalia Bodunova
LTLarisa Tsapkova
Larisa Tsapkova
ВПВера Полякова
Вера Полякова
IBIrina Baratova
Irina Baratova
KRKonstantin A. Rumyantsev
Konstantin A. Rumyantsev
Dmitry S BordinDmitry S Bordin
Dmitry S Bordin
The Maastricht VI/Florence consensus recommends, as one of the measures to enhance the efficacy of Helicobacter pylori (H. pylori) infection eradication, a personalized treatment approach involving the selection of an antimicrobial agent based on the pre-determined resistance of H. pylori. To meet the need to develop test systems for personalized drug selection, we conducted a study of H. pylori molecular resistance in Moscow using a self-developed Sanger sequencing test platform. We validated our test system on 25 pure culture samples of H. pylori with known resistance. Sensitivity and specificity for detecting resistance to clarithromycin was 100%, and to levofloxacin - 93% and 92%, respectively. Then we tested our platform on 112 H. pylori -positive patients who had not previously received proton pump inhibitors (PPI) or antibacterial drugs. Mutations indicating resistance to clarithromycin were found in 27 (24%) samples, and to levofloxacin in 26 (23%) samples. Double resistance was observed in 16 (14%) samples. The most common mutations leading to clarithromycin resistance were 2143G and 2142G, to levofloxacin resistance – 261A and 271A in the gyrA gene, which account for 69% of all identified genetic determinants in levofloxacin-resistant bacteria. Thus, a personalized approach to the selection of H. pylori eradication therapy based on the detection of bacterial resistance before prescribing first-line therapy could help avoid the prescription of ineffective H. pylori eradication therapies and, overall, contribute to the control of antibiotic resistance of H. pylori.